The cell and gene therapy (CGT) space continues to generate a lot of buzz. Amid ongoing funding challenges and getting clinical trials off the ground for Western biotechs, China is emerging as a dominant leader in the space.
This month’s cover feature examines the factors propelling China to become a leader of the pack in CGT amid a challenging global funding environment.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Also in this issue, we examine what impact the Trump administration distancing itself from mRNA technology could end up having on promising cancer vaccines over time.
As regulators push to phase out animal testing, this month’s interview sheds light on how the transition to alternative approaches may play out.
Read the latest issue of Pharma Technology Focus for all this and insights, and analysis from the pharmaceutical industry.
You can also subscribe here to receive email notifications when a new issue is available.
